VT-1598

VT-1598 is a novel, oral, small molecule antifungal agent developed by Viamet Pharmaceuticals (now Mycovia Pharmaceuticals). It is a highly selective inhibitor of fungal CYP51 (lanosterol 14α-demethylase), an enzyme essential for the synthesis of ergosterol in fungal cell membranes. VT-1598 was specifically designed to offer improved safety and efficacy over existing azole therapies by maximizing selectivity for the fungal enzyme over human cytochrome P450 enzymes, thereby potentially reducing drug-drug interactions and side effects. The drug is primarily being developed for the treatment of coccidioidomycosis (Valley fever), a serious fungal infection endemic to the southwestern United States, and has received Orphan Drug and Qualified Infectious Disease Product (QIDP) designations from the FDA.

Other names

VT-1598VT1598VT 1598